The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The primary goal of the collaboration is joint research into trending and next-generation molecules
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Subscribe To Our Newsletter & Stay Updated
